Novonesis

Solid Q1 2025 Fuels Optimism for FY25

09/05/25 -"Novonesis delivered a strong start to FY25, with 11% organic revenue growth and a 310bps expansion in adjusted EBITDA margin to 38.3%, both ahead of consensus. All segments and regions contributed to ..."

PDF page sample
Pages
51
Language
English
Published on
09/05/25
Download
You may also be interested by these reports :
06/02/26
Q4 ‘25 results exceeded consensus, as Lundbeck met its 2025 guidance. Strong growth for depression treatment Rexulti and migraine medicine Vyepti ...
05/02/26
The hugely discounted pricing announced by Hims & Hers for copycat pill versions of Novo’s semaglutide (for weight loss) seems perplexing, as they ...
05/02/26
The Q4 25 performance exceeded expectations, ensuring that GSK delivered on the higher end of the 2025 guidance. HIV, Respiratory, Immunology and ...
04/02/26
The Q4 performance, even though subdued, ensured that Novartis met the management’s 2025 guidance. Healthy Q4 growth across most key areas was ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO